查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870669

犬用疫苗市场按疫苗类型、通路、最终用户、技术和动物年龄组别划分－2025-2032年全球预测

Dog Vaccines Market by Vaccine Type, Distribution Channel, End User, Technology, Animal Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，犬类疫苗市场规模将达到 41.8 亿美元，复合年增长率为 8.26%。

关键市场统计数据
基准年 2024 22.1亿美元
预计年份：2025年 24亿美元
预测年份 2032 41.8亿美元
复合年增长率 (%) 8.26%

对现代犬用疫苗环境的简要概述，将科学创新与商业性现实和营运影响联繫起来。

科学技术的进步、宠物饲主期望的改变以及监管趋势的演变，共同推动犬类医疗保健领域的持续发展。本执行摘要介绍犬用疫苗领域的研究，概述了影响相关利益者决策的关键驱动因素、新兴方法和商业性格局。其目标是为企业主管、临床医生和产品负责人提供指导，帮助他们了解影响疫苗研发、分销和应用的结构性动态，并着重阐述其对营运和投资优先顺序的实际意义。

技术进步的融合、兽医护理模式的演变以及监管力度的加强如何推动犬用疫苗研发和供应的结构性变革

近年来，犬类疫苗的研发、评估和交付方式发生了许多转折点，这不仅为价值链上的相关人员带来了机会，也带来了挑战。分子平台技术的进步开闢了新的治疗途径，而低温运输物流和数位健康技术的同步发展则革新了分销模式，并为宠物饲主和兽医专业人员之间的互动方式创造了新的空间。这些变化也反映了人们期望的更广泛转变。宠物饲主越来越像关注自身健康一样关注宠物的健康，这推动了对更佳安全性和透明疗效数据的需求。

评估2025年美国关税对供应链韧性、采购决策和下游采购经济性的策略影响

美国贸易政策的发展和关税调整为采购计划、跨境伙伴关係以及关键物资供应带来了新的变数。关税变化不仅影响成品疫苗的运输，也影响上游原料、试剂和生产所需专用设备的流通。由于关税波动会影响最终到岸成本，并促使企业将某些生产活动在地化，各组织正在重新审视筹资策略，并评估建立区域生产中心的可行性，以降低贸易波动带来的风险。

整合疫苗类型、通路特征、终端用户偏好、技术平台和动物年龄组的可操作細項分析，以指导优先策略选择。

了解细分市场的细微差别对于根据疫苗类型、通路、终端用户需求、技术平台和动物年龄组来製定产品开发和上市策略至关重要。就疫苗类型而言，灭活疫苗、减毒活病毒疫苗和重组疫苗在开发和临床特征方面存在显着差异，每种疫苗都具有独特的安全性和储存特性，这些特性会影响临床应用和传播策略。在分销方面，通路分为机构管道和消费者管道，兽医诊所、线上零售商、药房和动物诊疗机构各自以不同的方式影响着诊疗行为、库存模式和客户体验。

一个综合考虑美洲、欧洲、中东和非洲以及亚太地区监管差异、分销管道能力和文化态度的全面区域观点

区域趋势在塑造犬用疫苗的监管时间表、分销基础设施和竞争格局方面发挥着至关重要的作用，每个主要区域都呈现出独特的商业环境。在美洲，对伴侣动物医疗保健服务的高度重视，加上成熟的兽医网络和私营部门对新型平台的大力投资，使得新配方在获得监管核准和类似报销机制后能够迅速得到推广应用。同时，欧洲、中东和非洲则形成了一个更多元化的生态系统，其监管协调程度、兽医机构密度和购买力各不相同。所有这些都要求制定量身定制的上市和市场准入策略，充分考虑各区域的合规性和流通结构。

策略竞争分析表明，现有企业的优势、生物技术创新和生产合作如何结合起来，在犬用疫苗领域创造差异化优势。

犬用疫苗领域的竞争由成熟的兽用生技药品公司、创新生物技术参与企业契约製造(CMO) 共同推动。儘管现有企业在分销网络、兽医信任度和监管经验方面保持优势，但新参与企业通常具有平台灵活性和差异化方法，能够快速适应新的靶点，例如基于 mRNA 或载体的构建体。合作和授权是将商业性覆盖范围与技术创新相结合的常用方式。对于那些希望加快产品上市速度并避免在固定资产上进行过多资本投资的公司而言，与合约开发和生产组织 (CDMO) 建立策略联盟也至关重要。

为经营团队提供切实可行的、优先排序的策略建议，以协调创新、供应链韧性、相关人员参与和分销执行，从而确保可持续优势。

动物健康领导企业应务实地结合创新投资、供应链强化和相关人员参与，以掌握机会并管控风险。首先，他们应优先考虑能够满足未满足的临床需求且具备可扩展生产能力的平台技术。这意味着评估DNA、mRNA和载体技术时，不仅要考虑其免疫学潜力，还要考虑其可生产性、低温运输影响和调节途径。同时，他们应制定灵活的筹资策略，包括关键试剂的双源供应，并考虑区域生产方案，以降低关税和运输中断带来的风险。

我们透过严格的混合方法调查方法来检验策略见解，该方法整合了关键相关利益者访谈、二手技术文献和情境分析。

本研究采用混合方法，整合质性和量性数据，强调检验和跨学科检验。主要数据来源包括对兽医、实验室技术人员、采购负责人和行业高管的结构化访谈，以及针对相关利益者的研讨会，旨在揭示该领域运营中的限制和应用驱动因素。次要资料来源包括监管指导文件、同行评审文献、临床试验报告和专利揭露，以确保技术准确性，并将技术趋势置于科学规范的框架下进行分析。

综合策略要务与实际考量，指导各组织在市场中稳健、实证地推广犬用疫苗。

总之，犬用疫苗领域处于科学创新、不断演进的分销模式以及复杂的监管和贸易环境的交汇点。能够成功驾驭这一领域的相关人员，是那些能够将平台技术进步转化为具有临床意义的产品、调整分销和教育以满足终端用户期望，并设计能够抵御政策和物流干扰的供应链的机构。其战略要务是将技术雄心与营运务实相结合，以确保新的疫苗能够安全可靠地惠及动物及其饲主，并建立长期的信任。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大基于mRNA的犬用疫苗的应用，以对抗新出现的感染疾病
  • 针对多种犬类病原体的新型多价疫苗监管核准进展
  • 家用自动注射器输送系统在犬隻常规疫苗接种通讯协定中的需求不断增长
  • 整合数位化疫苗接种追踪平台，以优化犬隻疫苗接种合规性
  • 推广联合疫苗以减少就诊次数并提高宠物饲主依从性
  • 根据犬隻基因风险分析结果制定个人化疫苗接种方案并进行推广。
  • 透过生技公司与动物医院连锁机构的策略合作，加速疫苗研发。
  • 口服和经鼻吸入型疫苗製剂的快速成长，使得犬隻接种疫苗的过程更加轻鬆无压力。
  • 重视通用感染疾病预防推动了频谱犬用疫苗的投资。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章犬用疫苗疫苗类型划分）

  • 灭活疫苗
  • 减毒活病毒疫苗
  • 重组

第九章犬用疫苗市场（依通路划分）

  • 兽医诊所
  • 线上零售
  • 药局
  • 兽医诊所

第十章犬用疫苗市场（依最终用户划分）

  • 宠物主人
  • 研究所
  • 兽医诊所

第十一章犬用疫苗市场（依技术划分）

  • DNA
  • mRNA
    • 非复製型
    • 自放大
  • 向量

第十二章 依动物年龄组别分類的犬用疫苗市场

  • 成犬
  • 小狗
  • 老年犬

第十三章 各地区犬用疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章犬用疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国犬用疫苗市场概况

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • Ceva Sante Animale SA
    • Virbac SA
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • HIPRA, SLU
    • Phibro Animal Health Corporation
Product Code: MRR-1A1A064C028B

The Dog Vaccines Market is projected to grow by USD 4.18 billion at a CAGR of 8.26% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.21 billion
Estimated Year [2025] USD 2.40 billion
Forecast Year [2032] USD 4.18 billion
CAGR (%) 8.26%

A concise orientation to the contemporary canine vaccine environment that maps scientific innovation to commercial realities and operational implications

The landscape of canine health management is undergoing sustained evolution as scientific advances, shifting pet owner expectations, and regulatory developments converge. This executive summary introduces a focused exploration of the dog vaccines domain, outlining critical drivers, emergent modalities, and the commercial contours that influence stakeholder decision-making. The objective is to orient executives, clinicians, and product strategists to the structural dynamics shaping vaccine development, distribution, and adoption while highlighting the practical implications for operations and investment prioritization.

Across veterinary practice and companion animal care, vaccination remains a cornerstone of preventive medicine. Nonetheless, recent years have seen a widening array of vaccine technologies, diversified delivery pathways, and more sophisticated demand signals from pet owners who increasingly value safety, convenience, and evidence of efficacy. This introduction frames subsequent sections by underscoring the interplay between scientific innovation and market-facing execution, setting expectations for how strategic choices will affect organizational competitiveness and animal welfare outcomes.

Moving forward, the assessment emphasizes translation of scientific capability into accessible products, the influence of channel economics on uptake, and the role of regulatory clarity in enabling novel modalities. In doing so, it prepares readers to interpret segmentation-level insights, regional variances, and the implications of trade policy on planning horizons and procurement strategies.

How converging technological advances, shifting veterinary care models, and regulatory tightening are driving a structural transformation across canine vaccine development and delivery

Recent years have seen several transformative shifts that are reshaping how vaccines for dogs are developed, vetted, and delivered, creating both opportunities and constraints for stakeholders across the value chain. Advances in molecular platforms have opened new therapeutic pathways, while parallel progress in cold-chain logistics and digital health has altered distribution models and created room for novel engagement with pet owners and veterinary professionals. These shifts also reflect broader changes in expectations: pet owners increasingly view companion animal health through a lens of human-grade care, driving demand for higher safety profiles and more transparent efficacy data.

At the same time, regulatory agencies have become more proactive in articulating requirements for newer modalities, leading to clearer pathways for DNA, mRNA, and vector-based candidates but also imposing stringent demonstration of long-term safety. The proliferation of online retail and telehealth-enabled veterinary services has disrupted traditional distribution norms and forced incumbents to adapt service models and client communications. Furthermore, integration of genomic surveillance and pathogen mapping into routine practice is enabling more targeted vaccine design, shortening the loop between outbreak detection and product iteration.

Consequently, innovators and established manufacturers must balance accelerated R&D trajectories with rigorous evidence generation and supply chain resilience. As a result, strategic imperatives now include investment in platform interoperability, enhanced stakeholder education, and adaptive manufacturing capacity that can respond to both routine immunization schedules and emerging pathogen threats.

Assessing the strategic consequences of United States tariff measures in 2025 on supply chain resilience, sourcing decisions, and downstream procurement economics

Trade policy developments and tariff adjustments enacted by the United States have introduced new variables into planning for procurement, cross-border partnerships, and the supply of critical inputs. Tariff changes affect not only finished vaccine shipments but also the upstream flow of raw materials, reagents, and specialized equipment that are essential to production. As tariffs alter landed costs and create incentives to localize specific manufacturing activities, organizations are reassessing sourcing strategies and evaluating the feasibility of regional production hubs to mitigate exposure to trade volatility.

These shifts have also prompted companies to reexamine contractual frameworks with suppliers and distributors, placing greater emphasis on flexibility clauses and dual-sourcing arrangements. In parallel, licensors and contract manufacturers are exploring alternative commercial models that can cushion the impact of tariff-induced cost fluctuations, including long-term supply agreements and onshore capacity investments. For stakeholders engaged in clinical development, changes in import duties affecting laboratory reagents and animal health diagnostics are being monitored closely, since procurement timelines may be lengthened when sourcing corridors become less predictable.

Ultimately, the cumulative impact of tariff measures in 2025 is encouraging a strategic pivot toward resilient supply chain design, stronger supplier relationships, and greater transparency into total landed costs. Executives should consider tariff exposure as one component of a broader risk management framework that includes regulatory, operational, and reputational factors.

Actionable segmentation intelligence that aligns vaccine type, channel dynamics, end-user preferences, technological platforms, and animal age cohorts to inform prioritized strategic choices

A nuanced understanding of segmentation is essential for tailoring product development and go-to-market strategies across vaccine modality, distribution pathways, end-user needs, technological platforms, and animal age cohorts. When considering vaccine type, there is a clear differentiation in development and clinical profiling between inactivated preparations, live attenuated formulations, and recombinant constructs, each presenting unique safety and storage characteristics that influence clinical adoption and communication strategies. Transitioning to distribution considerations, channels span institutional settings and consumer-facing outlets, with Animal Hospitals, Online Retail, Pharmacies, and Veterinary Clinics each shaping point-of-care dynamics, stocking patterns, and customer experience in distinct ways.

End-user segmentation reveals divergent decision criteria: Pet Owners prioritize convenience, perceived safety, and value communication; Research Institutes focus on assay compatibility and reproducibility for experimental work; Veterinary Hospitals require proven efficacy, ease of administration, and reliable supply. Technological segmentation is particularly consequential as DNA, mRNA, and Vector platforms demonstrate different timelines for regulatory validation, manufacturing scaling, and cold-chain dependencies; within mRNA there is further technical distinction between Non-Replicating and Self-Amplifying formats, which carries implications for dosing, immunogenicity, and production throughput. Age-based segmentation underscores clinical differentiation across Adult, Puppy, and Senior cohorts, given that immune competency, dosing schedules, and comorbidity profiles vary with age and thereby impact safety monitoring and communication strategies.

Integrated segmentation analysis indicates that winning strategies will align product profiles with channel economics and end-user expectations while leveraging platform advantages selectively for age cohorts that realize the greatest clinical benefit. Accordingly, cross-functional planning teams should map segmentation intersections to prioritize clinical programs, distribution investments, and educational outreach that resonate with each stakeholder cluster.

Comprehensive regional vantage points that reconcile regulatory diversity, channel capacity, and cultural attitudes across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a fundamental role in shaping regulatory timelines, distribution infrastructure, and the competitive landscape for canine vaccines, with distinct operating contexts across major geographies. In the Americas, a strong emphasis on companion animal health services is paired with well-established veterinary networks and robust private-sector investment in novel platforms, which fosters rapid uptake of new formulations when regulatory clearance and reimbursement-like mechanisms align. Conversely, Europe, Middle East & Africa presents a more heterogeneous ecosystem characterized by variable regulatory harmonization, differences in veterinary practice density, and diverse purchasing power, all of which necessitate tailored launch and access strategies that account for localized compliance and channel structures.

Asia-Pacific exhibits a mix of high-volume markets with rapidly modernizing veterinary infrastructure and emerging regions where access constraints and differing clinical priorities shape demand. Across all regions, cold-chain logistics, import regulations, and local manufacturing capacity influence placement decisions and partnership models. Moreover, cultural attitudes toward pet ownership, preventive care awareness, and the role of veterinarians in guiding vaccination choices introduce behavioral nuances that companies must address through locally adapted education and outreach programs.

Taken together, regional planning should emphasize regulatory due diligence, partnership selection that leverages local channel strengths, and investment in distribution capabilities that reflect the operational realities of each geography. This regional sensitivity will enable more effective product rollouts and greater alignment with clinician and pet owner expectations.

Strategic competitive landscape analysis showing how incumbent strengths, biotech innovation, and manufacturing partnerships converge to create differentiated advantage in the canine vaccine sector

Competitive dynamics in the dog vaccine sector are being influenced by a mix of established veterinary biologics firms, innovative biotechnology entrants, and contract manufacturers that support specialized platform scale-up. Incumbents retain advantages in distribution networks, practitioner trust, and regulatory experience, while newer entrants often bring platform agility and differentiated approaches such as mRNA or vector-based constructs that can be adapted rapidly to emerging targets. Partnerships and licensing deals are common mechanisms to combine commercial reach with technical novelty, and strategic alliances with contract development and manufacturing organizations are critical for firms seeking to accelerate time-to-market without overextending capital investment in fixed assets.

In addition, increasing emphasis on data-driven safety monitoring and post-marketing evidence collection is favoring competitors that can integrate digital tools and real-world data capture into their product propositions. Companies that invest in robust pharmacovigilance frameworks and clinician education programs are more likely to build long-term trust with veterinary professionals and pet owners. Meanwhile, supply chain reliability and the ability to manage cold-chain-sensitive products at scale remain differentiators that affect commercial sustainability. Consequently, market leaders will be those that combine technological innovation with operational excellence and a disciplined approach to regulatory engagement and stakeholder communication.

Practical and prioritized strategic recommendations for executives to align innovation, supply chain resilience, stakeholder engagement, and distribution execution for sustained advantage

Leaders in the animal health arena should pursue a pragmatic blend of innovation investment, supply chain fortification, and stakeholder engagement to capture opportunity while managing risk. First, prioritize platform technologies that align with clinical unmet needs and can be supported by scalable manufacturing; this means evaluating DNA, mRNA, and vector approaches not only for their immunological potential but for manufacturability, cold-chain implications, and regulatory pathways. Concurrently, develop flexible sourcing strategies that include dual suppliers for critical reagents and consider regional production options to reduce exposure to tariff and shipping disruptions.

Second, invest in clinician and owner education to foster confidence in newer modalities and to clarify administration schedules across life stages from puppy through senior animals. Third, enhance pharmacovigilance and real-world evidence programs to accelerate acceptance and to inform iterative product improvement. Fourth, design distribution strategies that reflect channel-specific behaviors, ensuring that Animal Hospitals, Online Retail, Pharmacies, and Veterinary Clinics each receive tailored product presentation, training, and logistical support. Finally, cultivate strategic partnerships with research institutions and contract manufacturers to balance in-house capability with external expertise and capacity, enabling rapid responses to pathogen emergence while maintaining operational discipline.

A rigorous mixed-methods research approach that integrates primary stakeholder interviews, secondary technical literature, and scenario analysis to validate strategic insights

This research synthesizes qualitative and quantitative inputs through a mixed-methods approach that emphasizes triangulation and subject-matter validation. Primary inputs include structured interviews with veterinary clinicians, laboratory scientists, procurement professionals, and industry executives, complemented by targeted stakeholder workshops that surfaced on-the-ground operational constraints and adoption drivers. Secondary sources encompass regulatory guidance documents, peer-reviewed literature, clinical trial reports, and patent disclosures to ensure technical accuracy and to situate technological trends within the scientific canon.

Analytical methods included cross-segmentation mapping to identify high-impact intersections among vaccine type, distribution channels, end-user priorities, technology platform, and animal age group. Scenario analysis was applied to evaluate supply chain and trade-policy sensitivities, while expert review panels validated assumptions and interpretation of complex technical issues. Throughout the process, care was taken to corroborate claims with multiple evidence streams and to document uncertainty explicitly, enabling readers to distinguish between well-supported insight and areas requiring further empirical work. This methodological rigor underpins the recommendations and ensures that strategic choices are grounded in a defensible evidentiary base.

A synthesis of strategic imperatives and practical considerations that guide organizations toward resilient, evidence-driven deployment of canine vaccines across markets

In closing, the dog vaccines domain sits at the intersection of scientific innovation, evolving distribution models, and complex regulatory and trade environments. Stakeholders who successfully navigate this space will be those that translate platform advances into clinically meaningful products, adapt distribution and education to meet end-user expectations, and design supply chains that withstand policy and logistical disruption. The strategic imperative is to couple technological ambition with operational pragmatism so that new modalities can reach animals and owners safely, reliably, and in a way that supports long-term trust.

Looking ahead, the organizations that win will be those that build adaptive capability across R&D, manufacturing, and commercial operations, while maintaining a relentless focus on evidence generation and stakeholder communication. By aligning segmentation-specific product design with regional realities and robust risk management, leaders can achieve durable impact in improving canine health outcomes and in creating sustainable commercial pathways for next-generation vaccines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of mRNA-based canine vaccines to combat emerging infectious diseases
  • 5.2. Regulatory approval progress for novel multivalent vaccines targeting multiple canine pathogens
  • 5.3. Rising demand for at-home auto-injector delivery systems in routine dog vaccination protocols
  • 5.4. Integration of digital immunization tracking platforms to optimize canine vaccination compliance
  • 5.5. Expansion of combination vaccines reducing veterinary visits and improving owner adherence
  • 5.6. Growth of personalized vaccination schedules based on canine genetic risk profiling
  • 5.7. Strategic partnerships between biotech innovators and veterinary chains to accelerate vaccine R&D
  • 5.8. Surge in oral and intranasal vaccine formulations for stress-free canine administration
  • 5.9. Focus on zoonotic disease prevention driving investment in broad-spectrum dog vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dog Vaccines Market, by Vaccine Type

  • 8.1. Inactivated
  • 8.2. Live Attenuated
  • 8.3. Recombinant

9. Dog Vaccines Market, by Distribution Channel

  • 9.1. Animal Hospitals
  • 9.2. Online Retail
  • 9.3. Pharmacies
  • 9.4. Veterinary Clinics

10. Dog Vaccines Market, by End User

  • 10.1. Pet Owners
  • 10.2. Research Institutes
  • 10.3. Veterinary Hospitals

11. Dog Vaccines Market, by Technology

  • 11.1. DNA
  • 11.2. mRNA
    • 11.2.1. Non-Replicating
    • 11.2.2. Self-Amplifying
  • 11.3. Vector

12. Dog Vaccines Market, by Animal Age Group

  • 12.1. Adult
  • 12.2. Puppy
  • 12.3. Senior

13. Dog Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dog Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dog Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Zoetis Inc.
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. Boehringer Ingelheim International GmbH
    • 16.3.4. Elanco Animal Health Incorporated
    • 16.3.5. Ceva Sante Animale S.A.
    • 16.3.6. Virbac S.A.
    • 16.3.7. Vetoquinol S.A.
    • 16.3.8. Dechra Pharmaceuticals PLC
    • 16.3.9. HIPRA, S.L.U.
    • 16.3.10. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DOG VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DOG VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DOG VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DOG VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DOG VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DOG VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS DOG VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS DOG VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GCC DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. GCC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. GCC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. GCC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. GCC DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. GCC DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GCC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. GCC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. GCC DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 266. GCC DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 267. GCC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GCC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. G7 DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. G7 DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. G7 DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. G7 DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. G7 DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. G7 DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. G7 DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. G7 DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. G7 DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 308. G7 DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 309. G7 DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. G7 DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. NATO DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. NATO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. NATO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. NATO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. NATO DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. NATO DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. NATO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. NATO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. NATO DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 322. NATO DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 323. NATO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. NATO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED STATES DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 339. CANADA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. CANADA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. CANADA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 342. CANADA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 343. CANADA DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. CANADA DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. CANADA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 346. CANADA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 347. CANADA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 348. CANADA DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 349. CANADA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 350. CANADA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 351. MEXICO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. MEXICO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 353. MEXICO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 354. MEXICO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 355. MEXICO DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 356. MEXICO DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 357. MEXICO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 358. MEXICO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 359. MEXICO DOG VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 360. MEXICO DOG VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 361. MEXICO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 362. MEXICO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 363. BRAZIL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 364. BRAZIL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 365. BRAZIL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 366. BRAZIL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 367. BRAZIL DOG VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 368. BRAZIL DOG VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 369. BRAZIL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)

TA